Literature DB >> 8406999

Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines.

R Brown1, C Clugston, P Burns, A Edlin, P Vasey, B Vojtĕsek, S B Kaye.   

Abstract

We have examined p53 protein levels in cell lines selected for resistance to the chemotherapeutic drug cis-diamminedichloroplatinum (II), cisplatin. The majority of the independent cisplatin-resistant clones isolated by a single selection with cisplatin from the ovarian tumour cell line A2780 showed increased levels of p53 protein compared to the parental cell line. Elevated p53 protein levels were also observed in cisplatin-resistant ovarian human tumour lines isolated after multiple exposures to cisplatin (A2780/cp70 and OVIP/DDP). Direct PCR sequencing of p53 cDNAs showed that both the A2780/cp70 and the parental A2780 cell lines had a wild-type p53 gene sequence. The OVIP and OVIP/DDP lines both had a heterozygous mutation at codon 126. Cell-cycle analysis after gamma-irradiation or cisplatin treatment showed evidence of a G1/S and G2/M cell-cycle checkpoint in both A2780/cp70 and the sensitive parental cell lines. However, the resistant cell line A2780/cp70 showed less inhibition of DNA synthesis after gamma-irradiation than the sensitive cell line. Transfection of a mutant p53 gene construct (containing a mutation at codon 143, val to ala) into the A2780/cp70 resistant cells conferred a significantly increased sensitivity to cisplatin, suggesting that p53 is a direct determinant of cisplatin resistance in these cells. However, expression of this mutant p53 in the A2780 cells did not affect sensitivity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406999     DOI: 10.1002/ijc.2910550428

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  37 in total

1.  Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.

Authors:  Douglas D Taylor; Cicek Gercel-Taylor; Lynn P Parker
Journal:  Gynecol Oncol       Date:  2009-07-31       Impact factor: 5.482

Review 2.  The two faces of tumor suppressor p53.

Authors:  M L Smith; A J Fornace
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

3.  Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.

Authors:  Chithra D Palani; James F Beck; Jürgen Sonnemann
Journal:  Invest New Drugs       Date:  2010-08-03       Impact factor: 3.850

4.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.

Authors:  A Saito; T Yamashita; Y Mariko; Y Nosaka; K Tsuchiya; T Ando; T Suzuki; T Tsuruo; O Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

5.  Identification of semaphorin E as a non-MDR drug resistance gene of human cancers.

Authors:  T Yamada; R Endo; M Gotoh; S Hirohashi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

6.  Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells.

Authors:  T Efferth; U Fabry; P Glatte; R Osieka
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

7.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

8.  Drug resistance in ovarian cancer - the role of p53.

Authors:  R Petty; A Evans; I Duncan; C Kurbacher; I Cree
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

9.  Alterations of T cell activation signalling and cytokine production by postmenopausal estrogen levels.

Authors:  Lowell T Ku; Cicek Gercel-Taylor; Steven T Nakajima; Douglas D Taylor
Journal:  Immun Ageing       Date:  2009-03-05       Impact factor: 6.400

10.  In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.

Authors:  R E Aird; J Cummings; A A Ritchie; M Muir; R E Morris; H Chen; P J Sadler; D I Jodrell
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.